| Complete Care At Harston Hall Llc | |
| 350 Haws Lane, Flourtown, Pennsylvania 19031 | |
| (215) 233-0700 | |
| Name | Complete Care At Harston Hall Llc |
|---|---|
| Location | 350 Haws Lane, Flourtown, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 72.17% |
| Medicare ID (CCN) | 395791 |
| Legal Business Name | 350 Haws Lane Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1215518949 |
| Organization Name | COMPLETE CARE AT HARSTON HALL LLC |
| Address | 350 Haws Ln, Flourtown, PA 19031 |
| Phone Number | 215-233-0700 |
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
| NPI Number | 1376580779 |
| Organization Name | GENESIS ELDERCARE CENTERS-HARSTON, INC. |
| Doing Business As | HARSTON HALL |
| Address | 350 Haws Ln, Flourtown, PA 19031 |
| Phone Number | 215-233-0700 |
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
| NPI Number | 1730361049 |
| Organization Name | 350 HAWS LANE OPERATIONS LLC |
| Doing Business As | HARSTON HALL |
| Address | 350 Haws Ln, Flourtown, PA 19031 |
| Phone Number | 215-233-0700 |
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
| NPI Number | 1831511864 |
| Organization Name | GENESIS ELDERCARE REHABILITATION SERVICES |
| Address | 350 Haws Ln, Flourtown, PA 19031 |
| Phone Number | 215-836-3242 |
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $19110 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.69 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 26.09 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.43 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.03 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.36 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.62 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.79 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.7 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 69.59 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.22 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 43.7 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20.2 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.99 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.24 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.93 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 68 | 82.93 |
News Archive
Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.
The continually rising health care costs in Germany require cost intelligent innovations at the intersecting frontiers of scientific disciplines.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/)
› Verified 8 days ago
Saint Joseph Villa Location: 110 West Wissahickon Ave, Flourtown, Pennsylvania 19031 Phone: (215) 836-4179 | |
Complete Care At Harston Hall Llc Location: 350 Haws Lane, Flourtown, Pennsylvania 19031 Phone: (215) 233-0700 |